{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:29:46Z","timestamp":1790958586102,"version":"4.1.0"},"reference-count":30,"publisher":"American Society of Hematology","issue":"22","license":[{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The Virtual Opinions poll Independent Centered on CLL patients\u2019 Experience (VOICE) evaluated patients\u2019 knowledge about chronic lymphocytic leukemia (CLL), their perspectives on diagnosis and treatment, and their unmet needs. Clinicians and patient advocacy group representatives developed and distributed the survey from March through December 2022 in 12 countries, and 377 patients with \u22651 line of previous CLL treatment responded from Europe, Latin America, the United States, Australia, Egypt, and Turkey. A majority of them (90%; 336\/374) relied on their physicians for information regarding CLL and treatment. If at high risk, respondents prefer oral medications to intravenous (78%; 232\/296), fixed duration treatment over treatment until progression (69%; 185\/270), outpatient over inpatient treatments (91%; 257\/283). Over three-fourths of respondents (78%; 286\/368) wanted to be involved in treatment decisions, but a minority actually participated (44%; 138\/313). COVID-19 vaccinations were widely available (97%; 273\/281), but one-fifth (19%; 63\/331) were unaware that CLL increases vulnerability to infections. Most patients\u2019 physicians explained their treatment options (84%; 297\/355), and 90% (271\/301) understood their treatment. Notably, &amp;gt;10% would continue treatment normally if they experienced cardiac problems or arrhythmias, whereas 23% would consider stopping treatment if they developed skin cancer. Treatment\u2013associated side effects affected 27% to 43% of patients. These results in a global patient population highlight gaps in patients\u2019 knowledge of risk groups, their susceptibility to infections including COVID, and the side effects of common treatments. Such knowledge can guide the appropriate targeting of patient education initiatives by clinicians, advocates, and policymakers.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010879","type":"journal-article","created":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T22:04:21Z","timestamp":1695074661000},"page":"6819-6828","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Results of VOICE: a global survey of disease-specific knowledge and perspectives of real-world patients with CLL"],"prefix":"10.1182","volume":"7","author":[{"given":"Constantine","family":"Tam","sequence":"first","affiliation":[{"name":"1Lymphoma Service, Alfred Hospital and Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pinilla-Ibarz","sequence":"additional","affiliation":[{"name":"2Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7079-3091","authenticated-orcid":false,"given":"Carolina G.","family":"Castillo","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Hospital Star Medica Lomas Verdes, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Cristina","family":"Fenili","sequence":"additional","affiliation":[{"name":"4Hospital Nossa Senhora da Concei\u00e7\u00e3o, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1722-9920","authenticated-orcid":false,"given":"Kathryn","family":"Huntley","sequence":"additional","affiliation":[{"name":"5Health Services, Leukaemia Foundation, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkan","family":"Karakus","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Antalya Research and Training Hospital, Antalya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervat","family":"Mattar","sequence":"additional","affiliation":[{"name":"7Hematology Unit, Department of Internal Medicine, Cairo University, Giza, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Miroli","sequence":"additional","affiliation":[{"name":"8Hospital M\u00e9dico Policial Churruca-Visca, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Moura","sequence":"additional","affiliation":[{"name":"9Associa\u00e7\u00e4o Brasileira De Linfoma E Leucemia, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4561-3153","authenticated-orcid":false,"given":"Miguel","family":"Pavlovsky","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Fundacion para Combatir la Leucemia, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Piotrowski","sequence":"additional","affiliation":[{"name":"11Asociaci\u00f3n Leucemia Mieloide de Argentina, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0331-5334","authenticated-orcid":false,"given":"Martin","family":"\u0160imkovi\u010d","sequence":"additional","affiliation":[{"name":"124th Department of Internal Medicine, University Hospital Hradec Kr\u00e1lov\u00e9, Hradec Kr\u00e1lov\u00e9, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Stilgenbauer","sequence":"additional","affiliation":[{"name":"13Department of Internal Medicine III, University of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,11,15]]},"reference":[{"issue":"2","key":"2023112721412747900_bib1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/annonc\/mdw547","article-title":"Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an International Society of Geriatric Oncology (SIOG) task force","volume":"28","author":"Stauder","year":"2017","journal-title":"Ann Oncol"},{"key":"2023112721412747900_bib2","doi-asserted-by":"crossref","first-page":"840616","DOI":"10.3389\/fonc.2022.840616","article-title":"Trends in disease burden of chronic lymphocytic leukemia at the global, regional, and national levels from 1990 to 2019, and projections until 2030: a population-based epidemiologic study","volume":"12","author":"Ou","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"2023112721412747900_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12938-021-00973-6","article-title":"The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019","volume":"21","author":"Yao","year":"2022","journal-title":"Biomed Eng Online"},{"issue":"2","key":"2023112721412747900_bib4","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2016.68.2856","article-title":"Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States","volume":"35","author":"Chen","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2023112721412747900_bib5","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023112721412747900_bib6","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"2023112721412747900_bib7","unstructured":"Surveillance, epidemiology, and end results (SEER) program. SEER cancer stat facts: leukemia--chronic lymphocytic leukemia (CLL). National Cancer Institute. Accessed 24 January 2023. https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html."},{"issue":"8","key":"2023112721412747900_bib8","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1002\/cam4.2268","article-title":"Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States","volume":"8","author":"Kabadi","year":"2019","journal-title":"Cancer Med"},{"key":"2023112721412747900_bib9","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1200\/EDBK_200691","article-title":"Approaches to chronic lymphocytic leukemia therapy in the era of new agents: the conundrum of many options","volume":"38","author":"Jain","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2023112721412747900_bib10","doi-asserted-by":"crossref","first-page":"2333721416630492","DOI":"10.1177\/2333721416630492","article-title":"Health literacy and older adults: a systematic review","volume":"2","author":"Chesser","year":"2016","journal-title":"Gerontol Geriatr Med"},{"issue":"1","key":"2023112721412747900_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40271-020-00440-9","article-title":"Development of a conceptual model of chronic lymphocytic leukemia to better understand the patient experience","volume":"14","author":"Eek","year":"2021","journal-title":"Patient"},{"issue":"suppl 16","key":"2023112721412747900_bib12","doi-asserted-by":"crossref","first-page":"12135","DOI":"10.1200\/JCO.2022.40.16_suppl.12135","article-title":"A comparative study of unmet information needs of patients with lymphoma and CLL: North America and Europe","volume":"40","author":"Bamigbola","year":"2022","journal-title":"J Clin Oncol"},{"issue":"S2","key":"2023112721412747900_bib13","first-page":"716","article-title":"Patient perspectives of chronic lymphocytic leukemia & disease related outcomes--a qualitative study","volume":"5","author":"Drupad","year":"2021","journal-title":"HemaSphere"},{"issue":"suppl 15","key":"2023112721412747900_bib14","doi-asserted-by":"crossref","first-page":"7532","DOI":"10.1200\/JCO.2018.36.15_suppl.7532","article-title":"The experiences of 1147 chronic lymphocytic leukemia (CLL) patients (pts) [abstract]","volume":"36","author":"Koffman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"24","key":"2023112721412747900_bib15","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/bloodadvances.2017007294","article-title":"Patients' priorities in selecting chronic lymphocytic leukemia treatments","volume":"1","author":"Mansfield","year":"2017","journal-title":"Blood Adv"},{"key":"2023112721412747900_bib16","unstructured":"Medicamentos\n          . La Administraci\u00f3n Nacional de Medicamentos, Alimentos y Tecnolog\u00eda M\u00e9dica. Accessed 4 September 2023. https:\/\/www.argentina.gob.ar\/anmat\/regulados\/medicamentos."},{"key":"2023112721412747900_bib17","unstructured":"Australian Register of Therapeutic Goods (ARTG)\n          . Department of Health and aged care therapeutic goods administration. Accessed 4 September 2023. https:\/\/www.tga.gov.au\/products\/australian-register-therapeutic-goods-artg."},{"key":"2023112721412747900_bib18","unstructured":"Medicamentos. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria\n          . . Accessed 23 September 2023. https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/medicamentos."},{"key":"2023112721412747900_bib19","unstructured":"Oficina Virtual Invima. Instituto Nacional de Vigilancia de Medicamentos y Alimentos. Accessed 4 September 2023. https:\/\/app.invima.gov.co\/ovirtual\/."},{"key":"2023112721412747900_bib20","unstructured":"Latest Articles. State Institute for Drug Control (SUKL). Accessed 4 September 2023. https:\/\/www.sukl.eu\/."},{"key":"2023112721412747900_bib21","unstructured":"National registers of authorised medicines. European Medicines Agency. Accessed 4 September 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/national-registers-authorised-medicines#human-medicines-section."},{"key":"2023112721412747900_bib22","unstructured":"Comisi\u00f3n Federal para la Protecci\u00f3n contra Riesgos Sanitarios. Government of Mexico. Accessed 4 September 2023. https:\/\/www.gob.mx\/cofepris\/."},{"key":"2023112721412747900_bib23","unstructured":"DIGEMID - Portal Institucional\n          . La Direcci\u00f3n General de Medicamentos, Insumos y Drogas. Accessed 4 September 2023. https:\/\/www.digemid.minsa.gob.pe\/webDigemid\/."},{"key":"2023112721412747900_bib24","unstructured":"Pharmacopoeia Department\n          . State Institute for Drug Control (SUKL). Accessed 4 September 2023. https:\/\/www.sukl.sk\/hlavna-stranka-1\/english-version\/pharmacopoeia\/pharmacopoeia-department?page_id=5252."},{"key":"2023112721412747900_bib25","unstructured":"Centro de informaci\u00f3n de medicamentos (CIMA). Ministerio de Sanidad. Accessed 4 September 2023. https:\/\/cima.aemps.es\/cima\/publico\/home.html."},{"key":"2023112721412747900_bib26","unstructured":"Medicines. Turkish Medicines and Medical Devices Agency (Titck). Accessed 9 September 2023. https:\/\/www.titck.gov.tr\/faaliyetalanlari\/ilac."},{"key":"2023112721412747900_bib27","unstructured":"Drugs@FDA: FDA-Approved Drugs. U.S. Food & Drug Administration. Accessed 4 September 2023. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm."},{"key":"2023112721412747900_bib28","unstructured":"Main page. Egyptian Drug Authority. Accessed 4 September 2023. https:\/\/www.edaegypt.gov.eg."},{"issue":"8","key":"2023112721412747900_bib29","doi-asserted-by":"crossref","first-page":"E199","DOI":"10.1002\/ajh.25851","article-title":"Management of CLL patients early in the COVID-19 pandemic: an international survey of CLL experts","volume":"95","author":"Koffman","year":"2020","journal-title":"Am J Hematol"},{"issue":"3","key":"2023112721412747900_bib30","doi-asserted-by":"crossref","first-page":"106275","DOI":"10.1016\/j.ijantimicag.2020.106275","article-title":"Passive immunization and its rebirth in the era of the COVID-19 pandemic","volume":"57","author":"Pavia","year":"2021","journal-title":"Int J Antimicrob Agents"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/22\/6819\/2109809\/blooda_adv-2023-010879-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/22\/6819\/2109809\/blooda_adv-2023-010879-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T21:41:53Z","timestamp":1701121313000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/22\/6819\/497952\/Results-of-VOICE-a-global-survey-of-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,15]]},"references-count":30,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2023,11,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010879","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,15]]}}}